Crandall Ryan 4
Research Summary
AI-generated summary
Marimed (MRMD) CCO Ryan Crandall Converts 54,000 RSUs to Shares
What Happened
Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), had 54,000 restricted stock units (RSUs convert-to-shares) vest and convert to common stock on June 8, 2026 (reported as an exercise/conversion of a derivative, code M). To satisfy tax withholding related to the vesting, 18,711 shares were withheld (reported under code F) at $0.08 per share, totaling about $1,413. After withholding, Crandall received a net 35,289 shares. The conversion had an exercise price of $0.00 per share (no cash exercise cost).
Key Details
- Transaction date: 2026-06-08
- Conversion/exercise: 54,000 RSUs → 54,000 shares (code M), exercise price $0.00
- Tax withholding: 18,711 shares withheld at $0.08/share = $1,413 (code F)
- Net shares received by insider: 35,289
- Shares owned after transaction: Not disclosed in the provided filing
- Notable footnotes: RSUs convert 1-for-1 to common stock; shares withheld to satisfy tax withholding; these RSUs were granted 6/8/2023 and this grant is now fully vested/settled.
- Filing status: Report filed on 2026-06-08 (same date as the transactions) — appears timely.
Context
This was a vesting/conversion of RSUs, not an open-market purchase or voluntary sale. The tax withholding is a routine cashless settlement to cover withholding obligations and does not necessarily indicate a change in the insider’s view of the company. For derivative entries like this, "exercise/conversion" here simply means the RSUs became common shares; no cash exercise payment was required.